Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

What mAbs tell us about shapes: multiple roads lead to Rome.

Alter G, Ackerman ME.

Immunity. 2013 Jan 24;38(1):8-9. doi: 10.1016/j.immuni.2013.01.003.

2.

Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.

Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M, et al.

J Virol. 1993 Oct;67(10):6136-51.

3.

Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.

Wu Z, Kayman SC, Honnen W, Revesz K, Chen H, Vijh-Warrier S, Tilley SA, McKeating J, Shotton C, Pinter A.

J Virol. 1995 Apr;69(4):2271-8.

4.
5.
7.
8.

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A.

J Immunol. 2002 Jul 1;169(1):595-605.

9.

Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, et al.

J Virol. 1993 Aug;67(8):4932-44.

14.

Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, Burda S, Wang XH, Bandres J, Zolla-Pazner S, Holmes H.

Immunol Lett. 2001 Dec 3;79(3):209-13.

PMID:
11600200
16.

The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Zhu CB, Zhu L, Holz-Smith S, Matthews TJ, Chen CH.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15227-32. Epub 2001 Dec 4.

17.

Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.

Sourial S, Nilsson C, Wärnmark A, Achour A, Harris RA.

Curr HIV Res. 2006 Apr;4(2):229-37.

PMID:
16611061
18.
19.

Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.

Liang X, Munshi S, Shendure J, Mark G 3rd, Davies ME, Freed DC, Montefiori DC, Shiver JW.

Vaccine. 1999 Jul 16;17(22):2862-72.

PMID:
10438057
20.

Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR.

J Virol. 1996 Jul;70(7):4598-606.

Supplemental Content

Support Center